In favor of an anti-tumorigenic PPARα action, Yokoyama and colleagues reported that treatment with clofibric acid, a PPARα agonist, reduced ovarian cancer cell growth and tumor angiogenesis in xenotransplanted animals. This evidence concerns the gene PPARA and ovarian cancer.